This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • PAM50 HER2-enriched phenotype as a predictor of ea...
Clinical trial

PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer

Read time: 1 mins
Last updated:12th Jul 2013
To evaluate the ability of the PAM50 HER2-enriched (HER2-E) subtype to predict pathological complete response in the breast (pCRB) to dual HER2 blockade with lapatinib and trastuzumab, with or without endocrine therapy, at the time of surgery.
Category Value
Study start date 2013-07-12

View full details